Email address for general EMBRACE related enquiries and for centres to order questionnaires and blood kit packs:
Candido-dos-Reis FJ et al. (2015) Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Clin Cancer Res.
Castro E et al. (2015) Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.
Pooley KA, McGuffog L, Barrowdale D, et al. (2014) Lymphocyte telomere length is longer in BRCA1 and BRCA2 mutation carriers but does not affect subsequent cancer risk.
Cancer Epidemiology, Biomarkers & Prevention
Philips KA et al. (2013) Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
J Clin Oncol.
Mavaddat N, Peock S, Frost D, et al. (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
J Natl Cancer Inst.
EMBRACE data are used in all publications from the CIMBA consortium.